CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Bladder Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Non Hodgkin Lymphoma
- Non -Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ovarian Cancer
- Pancreatic Cancer
- Triple -Negative Breast Cancer
- Renal Cell Cancer
- Sarcoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03454451
- Collaborators
- Not Provided
- Investigators
- Study Chair: S Mahabhashyam, MD Corvus Pharmaceuticals
Get Well Soon